During the past decade, Joliet Oncology-Hematology Associates, Limited - West conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 92 clinical trials were completed, i.e. on average, 368% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 22 clinical trials were completed. i.e. 550% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Joliet Oncology-Hematology Associates, Limited - West" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 58 trials, followed by "National Cancer Institute (NCI)" with 37 trials sponsored, "Eastern Cooperative Oncology Group" with 26 trials sponsored, "SWOG Cancer Research Network" with 22 trials sponsored and "Gynecologic Oncology Group" with 22 trials sponsored. Other sponsors include 76 different institutions and companies that sponsored additional 46 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Joliet Oncology-Hematology Associates, Limited - West" #1 collaborator was "National Cancer Institute (NCI)" with 135 trials as a collaborator, "NCIC Clinical Trials Group" with 12 trials as a collaborator, "Cancer and Leukemia Group B" with 11 trials as a collaborator, "Eastern Cooperative Oncology Group" with 9 trials as a collaborator and "North Central Cancer Treatment Group" with 7 trials as a collaborator. Other collaborators include 40 different institutions and companies that were collaborators in the rest 35 trials.

According to Clinical.Site data, the most researched conditions in "Joliet Oncology-Hematology Associates, Limited - West" are "Breast Cancer" (32 trials), "Lung Cancer" (18 trials), "Unspecified Adult Solid Tumor, Protocol Specific" (12 trials), "Lymphoma" (11 trials) and "Colorectal Cancer" (9 trials). Many other conditions were trialed in "Joliet Oncology-Hematology Associates, Limited - West" in a lesser frequency.

Most popular intervention types in "Joliet Oncology-Hematology Associates, Limited - West" are "Drug" (207 trials), "Other" (62 trials), "Biological" (59 trials), "Radiation" (28 trials) and "Procedure" (25 trials). Other intervention types were less common.

The name of intervention was led by "placebo" (24 trials), "Laboratory Biomarker Analysis" (22 trials), "Placebo" (14 trials), "carboplatin" (14 trials) and "cisplatin" (14 trials). Other intervention names were less common.

The vast majority of trials in "Joliet Oncology-Hematology Associates, Limited - West" are 180 trials for "All" genders, 42 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are NaN active trials in "Joliet Oncology-Hematology Associates, Limited - West". undefined are not yet recruiting, 5 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 169 completed trials in Joliet Oncology-Hematology Associates, Limited - West, undefined suspended trials, and 39 terminated clinical trials to date.

Out of the total trials that were conducted in Joliet Oncology-Hematology Associates, Limited - West, 12 "Phase 1" clinical trials were conducted, 104 "Phase 2" clinical trials and 110 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".